This trialwill assess a new epilepsy drug's effectiveness and safety in children with myoclonic-atonic seizures. Part A will assess efficacy & tolerability, Part B will assess long-term safety.
- Epilepsy-Associated Seizures (EMAS)
9 Primary · 24 Secondary · Reporting Duration: Weeks 14, 24, and 48
Side Effects for
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
240 Total Participants · 2 Treatment Groups
Primary Treatment: GWP42003-P · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 1 - 18 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there an age limit for participants in this particular research project?
"In order to take part in this research, potential participants must be aged 1-18. Out of the total 316 clinical trials, 126 are for people under 18 years old and 190 are for those over 65." - Anonymous Online Contributor
Are there any safety concerns associated with taking GWP42003-P?
"There is existing data that suggests GWP42003-P's efficacy and safety, so it was given a score of 3." - Anonymous Online Contributor
Are there any open slots for new volunteers in this clinical trial?
"Indeed, the most recent information available on clinicaltrials.gov points to this trial recruiting patients as we speak. This particular study was first advertised on October 31st 2020 and updated November 14th 2020. There is a need for 240 individuals at 1 site location." - Anonymous Online Contributor
How many individuals can join this clinical trial?
"The information available on clinicaltrials.gov verifies that this study is currently recruiting patients. The trial was posted on October 31st, 2020 and updated two weeks ago on November 14th. They are looking for a total of 240 subjects at a single location." - Anonymous Online Contributor
For whom is this trial designed?
"This trial is looking for 240 participants that suffer from seizures and are between 1 year old to 18 years old. Eligibility requirements include the following: contraceptive use by both male and female participants must follow Clinical Trial Facilitation Group (CTFG) guidelines, females cannot be pregnant or lactating, have a negative serum pregnancy test at Screening , confirmed negative urine pregnancy test before receiving IMP at Part A Visit 3, continuing to Part B with a negative urine pregnancy test result before receiving GWP42003-P, diagnosis of epilepsy with myoclonic-atonic seizures consistent with ILAE guidelines, initial seizure onset occurred 6 months to" - Anonymous Online Contributor